At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 13 enrolled

Drug / intervention

N-acetylcysteine +1 moredrug

Likely dose

N-acetylcysteine 600 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02579772

NCT02579772Phase 4Completed

Compare CT.gov

Systemic Vascular Dysfunction in COPD Patients With Mild-to-moderate Airflow Obstruction: Pharmacological Treatment With N-acetylcysteine

Queen's University·interventional·Posted Oct 20, 2015·Updated Jun 14, 2018

In Brief

A Phase 4 clinical trial evaluating N-acetylcysteine and Placebo for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 13 participants.

Detailed Summary

The main purpose of this study is to determine whether pharmacological treatment with N-acetylcysteine improves central and peripheral cardiorespiratory control and physical capacity in COPD patients with mild-to-moderate airflow obstruction.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsPulmonary Disease, Chronic Obstructive

Countries--

Collaborators--

Timeline

Phase 4CompletedFinished

20162017201820192020202120222023202420252026

Enrollment StartJul 2015

First PostedOct 2015

Primary CompletionMay 2016

TodayJul 2026

First PostedOct 20, 2015

Enrollment StartJul 1, 2015

Primary CompletionMay 1, 2016

TodayJul 2, 2026

Enrollment to primary: 10 monthsPosted 10.7 years ago

Interventions

N-acetylcysteinedrug

Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.

Placebodrug

Placebo: 3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.